Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (NCT06785090) | Clinical Trial Compass
CompletedPhase 4
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Iraq87 participantsStarted 2023-05-01
Plain-language summary
The goal of this clinical trial is to learn if bromfenac ophthalmic solution can prevent cystoid macular edema (CME) and reduce macular thickness in patients undergoing phacoemulsification surgery for cataract removal. The main questions it aims to answer are:
Does bromfenac reduce the incidence of CME after cataract surgery? Does bromfenac effectively control macular thickness postoperatively compared to standard care? investigators will compare the effects of bromfenac ophthalmic solution to a control group receiving standard postoperative treatment to see if bromfenac provides additional benefits.
Participants will:
Use bromfenac ophthalmic solution as prescribed postoperatively. Attend follow-up visits for macular thickness measurements and assessments of eye health.
Undergo routine postoperative evaluations to monitor for adverse effects.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All patients 18 years of age and older.
* Patients diagnosed with cataracts.
Exclusion Criteria:
* Patients less than 18 years of age.
* Patients with glaucoma, ocular hypertension, pseudo-exfoliation syndrome, or any optic nerve disease.
* Patients with ocular diseases that might influence macular thickness, such as:
* Age-related macular degeneration
* Epiretinal membrane
* History of uveitis
* Intraoperative complications
* Traumatic cases
* Patients who have undergone previous ocular surgery in the same eye, such as:
* Vitrectomy
* Intravitreal injection
* Retinal laser therapy
* Corneal surgery
* Patients who developed severe adverse effects from other drugs or had complications intraoperatively or postoperatively unrelated to bromfenac.
* Patients taking antiglaucoma medications.
* Patients lost to follow-up.
* Patients with an allergy to one of the postoperative medications.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Macular Thickness From Baseline to 6 Weeks Postoperatively After Cataract Surgery